Canntab to Commence Trading on CSE on 4/20

Canntab Therapeutics Limited (CSE:PILL) (formerly Telferscot Resources Inc.) (“Canntab” or the “Company”) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) at the opening of the market on Friday, April 20, 2018 under the stock symbol “PILL”.

Canntab Therapeutics Limited (CSE:PILL) (formerly Telferscot Resources Inc.) (“Canntab” or the “Company”) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) at the opening of the market on Friday, April 20, 2018 under the stock symbol “PILL”.

“We are proud to announce that Canntab has joined the growing family of cannabis companies listed on the CSE, and believe that this represents an important milestone for the Company and our loyal shareholders. Canntab was able to take this step on only the second anniversary from its date of incorporation, and we intend to continue taking steps like these to enhance shareholder value, increase liquidity and execute on our strategic vision,” said Jeff Renwick, CEO and a director of Canntab.

Stock Options

In connection with the CSE listing, the Company also announces that the board of directors has authorized the grant of 430,000 incentive stock options to certain of its directors, officers, employees and consultants. Each such option entitles the holder to acquire one common share for a period of 3 years at an exercise price of $1.00 per common share.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
info@canntab.ca

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation.

Source: www.newsfilecorp.com

Featured
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofCronos Group Inc. for violations of the securities lawsThe investigation focuses on whether the Company issued false andor misleading statements andor failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofCronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

read more Show less
The company's first ESG report outlines efforts to operate with integrity and support long-term sustainability Trulieve Cannabis Corp. the largest multi-state operator in the United States today announced the publication of its first Environmental, Social, and Governance Report . The Report contains standard disclosures from the Global Reporting Initiative Sustainability Reporting Standards, The Sustainability ...

The company's first ESG report outlines efforts to operate with integrity and support
long-term sustainability

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), the largest multi-state operator (MSO) in the United States today announced the publication of its first Environmental, Social, and Governance (ESG) Report (the "Report"). The Report contains standard disclosures from the Global Reporting Initiative (GRI) Sustainability Reporting Standards, The Sustainability Accounting Standards Board (SASB) as well as the United Nations Sustainable Development Goals. The Report highlights ESG achievements to date and serves as a foundation for demonstrating how the Company's ESG approach, strategies and commitments are embedded within its core business.

read more Show less
Pomerantz LLP is investigating claims on behalf of investors of Cronos Group Inc. . Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cronos and certain of its officers andor directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On ...

Pomerantz LLP is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Cronos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

read more Show less

MARKETS

Markets
TSX21149.00+23.10
TSXV954.26+10.21
DOW35135.94+236.60
S&P 5004655.27+60.65
NASD15782.83+291.18
ASX7239.80-39.50

COMMODITIES

Commodities
Gold1791.56+4.93
Silver22.79-0.14
Copper4.30-0.04
Palladium1795.11+6.19
Platinum952.52-13.47
Oil67.51-2.44
Heating Oil2.08-0.07
Natural Gas4.74-0.12